Introduction
Testosterone, classified as a Schedule III controlled substance under the Controlled Substances Act, is one of the most commonly prescribed medications in hormone therapy practices. Managing controlled substance prescribing appropriately—with the right documentation, monitoring, and regulatory compliance—is both a clinical and legal imperative. Practitioners who fail to comply with controlled substance regulations face DEA enforcement action, medical board discipline, and potentially criminal liability. This guide provides a compliance framework for controlled substance management in hormone therapy clinics.
DEA Registration Requirements
To prescribe testosterone and other Schedule III-V controlled substances, you must hold a current DEA registration. DEA registration must be renewed every three years. Your registration is tied to a specific practice address—if you move, open a new location, or expand to telehealth services that involve a different address, your DEA registration requirements may change. Maintain a current DEA registration for every practice location where you write controlled substance prescriptions.
State Prescription Monitoring Programs
Every state has a Prescription Monitoring Program (PMP) that tracks controlled substance prescriptions dispensed to patients. In most states, practitioners are required to check the PMP before prescribing controlled substances and to report prescriptions to the PMP within specified timeframes. Failure to check or report to the PMP is itself a regulatory violation. Integrate PMP checks into your prescribing workflow so they happen consistently for every patient every time.
Prescribing Testosterone: Documentation Requirements
To prescribe testosterone compliantly, your medical record must document: a clinical indication for testosterone therapy (documented symptoms and laboratory evidence of testosterone deficiency), discussion of risks and benefits, patient-signed informed consent, prescription details (medication name, dose, quantity, route of administration, refill authorization), and monitoring plan. A prescription for testosterone that lacks documented clinical indication is a controlled substance compliance violation.
Telehealth and Controlled Substance Prescribing
The Ryan Haight Act governs telehealth prescribing of controlled substances. It generally requires an in-person medical evaluation before prescribing a controlled substance via telemedicine. However, DEA has granted temporary exceptions (extended during and after COVID-19) and is developing a special telemedicine registration for qualifying practitioners. The regulatory landscape here is evolving—work with a healthcare attorney to ensure your telehealth controlled substance prescribing is compliant with current regulations.
Preventing Controlled Substance Diversion
Controlled substance diversion—the redirection of prescribed medications to unintended users or non-medical use—is a federal crime that can implicate prescribers who fail to take reasonable precautions. For testosterone, diversion risk is lower than for opioids or stimulants, but remains a concern particularly for injectable testosterone. Implement reasonable precautions: prescription monitoring program checks, documented clinical indication for every prescription, and a patient population that is clinically appropriate for the therapy you’re providing.
Conclusion
Controlled substance prescribing is one of the highest-risk regulatory areas for hormone therapy practitioners. The practitioners who manage it well do so through systematic compliance: proper DEA registration, consistent PMP checks, thorough documentation, and current knowledge of applicable regulations. Build these compliance practices into your workflows from day one, and manage them with the same rigor you apply to your clinical protocols.